Press releases

For media enquiries, please contact us.

News archive
14 Feb 2019, 10:05
HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces today that it will present a poster entitled “Targeting of HOX-PBX binding in glioblastoma multiforme as a novel therapeutic treatment” at the American Association for Cancer Research Annual Meeting 2019 in Atlanta, Georgia, USA.
28 Jan 2019, 10:28
HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces the appointment of Dr Stephen Shuttleworth as Non-Executive Director.
13 Nov 2018, 15:53
Developing Targeted Therapies With Potential Applicability Across Many Cancer Types